

## DITERPENOID COMPOUNDS FROM *Vitex agnus-castus*

Mahesh Pal,<sup>1,2\*</sup> Sheng-Hong Li,<sup>2</sup> Shri Krishan Tewari,<sup>1</sup>  
and Han-Dong Sun<sup>2</sup>

UDC 547.913.6


A new diterpenoid alkaloid having an  $\alpha,\beta$ -unsaturated  $\gamma$ -lactam moiety,  $9\alpha$ -hydroxy-13(14)-labden-16,15-amide (**1**), together with five known ones, was isolated from the fruits of *Vitex angus-castus*. The structure of **1** was elucidated by spectroscopic methods, including extensive 1D and 2D NMR techniques. The cytotoxicity of each compound was evaluated against human chronic myelogenous leukemia (K562) cell lines. Compound **1** was found to be the most potent with  $IC_{50}$  value of 0.70  $\mu$ g/mL.

**Keywords:** diterpenoid, *Vitex agnus-castus*, Verbenaceae, vitexlactam, cytotoxicity.

*Vitex agnus-castus* L. (Verbenaceae) is a medicinal plant distributed in tropical and temperate zones, the Mediterranean region, Central Asia, and Southern Europe [1]. It is also cultivated in Jiangsu and Shanghai of China. It is used in traditional medicine for the treatment of female hormonal disorders [2, 3]. In recent years, several papers have described phytochemistry investigations that show that plants in this genus produce diterpenoids [4–7], flavonoids [8–10], terpenoids, steroids [10], and iridoids [11]. The fruits of *V. agnus-castus* are popular phytomedicines in Europe [12, 13].

*Vitex agnus-castus* L. is widely distributed in Northwestern China. In previous work, some bioactive compounds were isolated from this plant [4–7, 10]. Motivated by a search for bioactive compounds from this plant, a reinvestigation of the chemical compounds of the fruits of *V. agnus-castus* was carried out. As a result, a new diterpenoid alkaloid (**1**), together with five known diterpenoids, was isolated from this plant. In addition, all the compounds (**1–6**) were evaluated for their cytotoxic activity against human-tumor K562 cells, with cisplatin as a positive control ( $IC_{50} = 1.10 \mu$ g/mL). Compound **1** showed the most potent effect against K562 cells with an  $IC_{50} = 0.70 \mu$ g/mL. Compounds **2**, **3**, and **4** displayed modest activities, and compounds **5** and **6** showed weak activities (Table 1).

The air-dried fruits of *V. agnus-castus* (5.75 kg) were milled sequentially and extracted three times with 70% EtOH. Evaporation of the solvent under reduced pressure provided a 70% EtOH extract (335 g). This crude extract was subjected repeatedly to column chromatography on silica gel, Sephadex LH-20, RP-18, and Chromatorex ODS to afford compounds **1–6**, including a new diterpenoid alkaloid (**1**), together with five known diterpenoids: vitexlactam (**2**) [14], vitexilactone and rotundifurans (**3**, **4**) [15], 8-epimanoyl oxide (**5**) [16], and vitetrifolin D (**6**) [17].



1) Phytochemistry Division, CSIR-National Botanical Research Institute Lucknow, 226 001, U. P., India, e-mail: drmpal.nbri@rediffmail.com; 2) State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, 650204, Kunming, Yunnan, P. R. China. Published in *Khimiya Prirodnnykh Soedinenii*, No. 4, July–August, 2013, pp. 544–546. Original article submitted June 7, 2012.

TABLE 1. Cytotoxic Effects of Compounds **1–6** in K562 Cell Lines

Compound	IC <sub>50</sub> , µg/mL	Compound	IC <sub>50</sub> , µg/mL
Cisplatin (control)	1.10	<b>4</b>	2.91
<b>1</b>	0.70	<b>5</b>	4.56
<b>2</b>	1.15	<b>6</b>	6.72
<b>3</b>	2.73		

TABLE 2. <sup>13</sup>C NMR Data of Compounds **1–6** (CDCl<sub>3</sub>, δ, ppm)

C atom	A [7]	<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>
1	33.7 t	32.5 t	33.7 t	33.8 t	33.9 t	36.5 t	25.9 t
2	18.8 t	18.7 t	18.6 t	18.9 t	18.7 t	20.7 t	19.4 t
3	43.8 t	41.7 t	43.6 t	43.9 t	43.7 t	42.3 t	39.4 t
4	33.9 s	33.3 s	34.0 s	34.3 s	34.8 s	32.9 s	34.6 s
5	47.5 d	46.2 d	47.6 d	48.0 d	47.5 d	46.3 d	132.5 s
6	70.6 d	21.7 t	69.9 d	70.1 d	70.3 d	21.0 t	66.2 d
7	36.3 t	36.8 t	36.1 t	36.4 t	36.1 t	37.9 t	72.7 d
8	32.1 d	31.4 d	31.9 d	32.3 d	33.6 d	74.1 s	36.4 d
9	76.4 s	76.8 s	76.7 s	76.8 s	76.8 s	61.2 d	42.9 s
10	44.0 s	43.3 s	43.8 s	44.1 s	43.7 s	38.9 s	141.5 s
11	32.3 t	32.0 t	32.3 t	31.9 t	31.8 t	18.6 t	29.3 t
12	21.7 t	22.0 t	26.5 t	25.7 t	21.5 t	45.1 t	38.6 t
13	140.6 s	140.8 s	163.6 s	171.3 s	125.5 s	73.6 s	73.0 s
14	137.1 d	136.9 d	121.2 d	115.3 d	110.8 d	146.1 d	144.5 d
15	46.6 t	46.4 t	175.3 s	171.3 s	142.9 d	111.1 t	112.1 t
16	175.3 s	175.8 s	50.5 t	73.4 t	138.5 d	27.4 q	27.8 q
17	16.4 q	16.6 q	16.0 q	16.3 q	16.1 q	32.0 q	11.1 q
18	33.6 q	33.7 q	33.6 q	33.8 q	33.6 q	33.1 q	29.3 q
19	23.7 q	22.1 q	23.6 q	23.9 q	23.7 q	21.3 q	28.1 q
20	18.9 q	16.2 q	19.0 q	19.2 q	19.0 q	24.7 q	28.0 q
AcO (C=O)	170.5 s		170.3 s	170.6 s	170.7 s		170.8 (2C, s)
AcO (CH <sub>3</sub> )	21.9 q			21.8 q	22.1 q		21.4 q
							20.9 q

Compound **1** was isolated as white crystals with molecular formula C<sub>20</sub>H<sub>33</sub>NO<sub>2</sub>, which was confirmed by high-resolution EI mass spectrometry (found: *m/z* 319.2509, calcd 319.2511). The existence of a nitrogen atom was supported by its odd-numbered molecular weight. The <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>, δ, ppm, J/Hz): 1.50 (1H, t, J = 11.0, H-5), 1.75 (1H, m, H-8), 1.78 (1H, m, H-11a), 1.67 (1H, m, H-11b), 2.36 (2H, br.t, J = 8.2, H<sub>2</sub>-12), 6.69 (1H, br.s, H-14), 3.89 (2H, br.s, H<sub>2</sub>-15), 0.88 (3H, d, J = 6.6, CH<sub>3</sub>-17), 0.85 (3H, s, CH<sub>3</sub>-18), 0.80 (3H, s, CH<sub>3</sub>-19), 0.90 (3H, s, CH<sub>3</sub>-20), 6.61 (1H, br.s, NH), and <sup>13</sup>C NMR (Table 1) spectra of **1**, being very similar to vitexlactam (**A**) [7], suggested that **1** is a labdane diterpenoid alkaloid closely related to **A** (Table 2) having an α,β-unsaturated γ-lactam moiety at the C-9 side chain **1** and differing from **A** only by the absence of the signals for an acetyl group and the replacement of an oxygen-bearing methine at δ<sub>C</sub> 70.6 by a methylene at δ<sub>C</sub> 21.7, which indicates that **1** is the 6-deacetoxy derivative of **A**. This was supported as well by the fact that **A** was 58 atomic mass units less than **1** and there was no acetoxy group observed in the IR spectrum of **1**.

## EXPERIMENTAL

**General.** UV spectral data were obtained on a UV 210A spectrometer. Optical rotations were carried out on a Horiba SEPA-300 High Sensitive Polarimeter or a Perkin–Elmer model 241 Polarimeter. 1D and 2D NMR experiments were performed either on a Bruker AM-400 or a DRX-500 spectrometer. Unless otherwise specified, chemical shifts (δ) are expressed in ppm with reference to the solvent signals. FAB-MS and HR-FAB-MS were taken on a VG Auto Spec-3000 or on a Finnigan MAT 90 instrument. IR spectra were recorded on a Bio-Rad FTS-135 spectrometer with KBr pellets. Column chromatography was

performed on silica gel (200–300 mesh, Qingdao Marine Chemical Inc., China), silica gel H (10–40  $\mu$ , Qingdao Marine Chemical Inc., China), Diaion HP-20 (Shandong Lukang Pharmaceutical Co., Ltd., China), Chromatorex ODS (Fuji Silysia Chemical Corporation, Ltd., Japan), and RP<sub>18</sub> gel (40–63  $\mu$ m, Merck, Darmstadt, Germany). The fractions were monitored by TLC, and spots were visualized by heating the silica gel plates sprayed with 5% H<sub>2</sub>SO<sub>4</sub> in EtOH.

**Plant Material.** The fruits of *V. agnus-castus* were purchased from Caojian town in Yunnan Province in China and identified by Prof. Xiao Cheng at Kunming Institute of Botany. A voucher specimen (KI-2007-25) was deposited in the Department of Taxonomy, Kunming Institute of Botany, Kunming, China.

**Extraction and Isolation.** The air-dried fruits of *V. agnus-castus* (5.75 kg) were milled sequentially and extracted three times with 70% EtOH. Evaporation of the solvent under reduced pressure provided a 70% EtOH extract (335 g). A suspension of the resulting extract in water was partitioned with *n*-hexane, CHCl<sub>3</sub>, EtOAc, and *n*-BuOH successively. The CHCl<sub>3</sub> extract (110 g) was fractionated by silica gel column chromatography (200–300 mesh) eluting with petroleum ether–acetone (100:1–100:100) to give seven fractions. Fraction 3 was separated by silica gel column chromatography (200–300 mesh) eluting with petroleum ether–acetone (8:1) and Sephadex LH-20 (CHCl<sub>3</sub>–MeOH, 1:1) to give compound **1** (20 mg). Fraction 5 was subsequently chromatographed using silica gel (petroleum ether–acetone, 100:20–50) and Chromatorex ODS (70% MeOH, 80% MeOH, 85% MeOH) to furnish compounds **2** (15 mg), **3** (13 mg), and **4** (18 mg). Fraction 6 was also subjected to silica gel column chromatography and eluted with CHCl<sub>3</sub>–acetone (100:1–100:30) to give five subfractions. Subfraction 1 (CHCl<sub>3</sub>–acetone, 100:5) was purified on chromatorex ODS (85% MeOH) to afford compound **5** (15 mg). Subfraction 3 (CHCl<sub>3</sub>–acetone, 100:30) was isolated on Chromatorex ODS (80% MeOH) to yield **6** (20 mg).

**9 $\alpha$ -Hydroxy-13(14)-labden-16,15-amide (1)** having an  $\alpha,\beta$ -unsaturated  $\gamma$ -lactam moiety. White crystals, mp 162°C, C<sub>20</sub>H<sub>33</sub>NO<sub>2</sub>, [ $\alpha$ ]<sub>D</sub><sup>23.5</sup> +18.7° (*c* 0.2, CHCl<sub>3</sub>). IR (KBr,  $\nu_{\text{max}}$ , cm<sup>−1</sup>): 3473, 3187, 3055, 2924, 2682, 1684, 1648, 1442, 1379, 1296, 1254, 1228, 1140, 1085, 1057, 1041, 1018, 972, 962, 943, 909, 832, 791, 777, 698. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>,  $\delta$ , ppm, J/Hz): 1.50 (1H, t, J = 11.0, H-5), 1.75 (1H, m, H-8), 1.78 (1H, m, H-11a), 1.67 (1H, m, H-11b), 2.36 (2H, br.t, J = 8.2, H<sub>2</sub>-12), 6.69 (1H, br.s, H-14), 3.89 (2H, br.s, H<sub>2</sub>-15), 0.88 (3H, d, J = 6.6, CH<sub>3</sub>-17), 0.85 (3H, s, CH<sub>3</sub>-18), 0.80 (3H, s, CH<sub>3</sub>-19), 0.90 (3H, s, CH<sub>3</sub>-20), 6.61 (1H, br.s, NH). For <sup>13</sup>C NMR data, see Table 1. EI-MS (*m/z*, *I*<sub>rel</sub>, %): 319 [M]<sup>+</sup> (81), 304 (7), 286 (8), 206 (7), 194 (19), 180 (100), 167 (75), 152 (11), 138 (47), 123 (17), 110 (81), 96 (86), 82 (58), 69 (72), 55 (97); HR-EI-MS *m/z* found 319.2509 [M]<sup>+</sup>, calcd 319.2511.

**Cell Cultures.** Chronic myelogenous leukemia (K562) human cell lines were obtained from the Shanghai Cell Bank, Chinese Academy of Sciences. The cells were maintained in RPMI 1640 medium with hormone-free 15% heat-inactivated FBS (fetal bovine serum). In each case, 2 mM glutamine, 100 U/mL penicillin G, and 100  $\mu$ g/mL streptomycin were added.

**Cytotoxic Assays.** The cytotoxicity tests for the isolates were performed using the reported protocol [18]. All treatments were performed in triplicate, and the results are shown in Table 1.

## ACKNOWLEDGMENT

The authors wish to thank the State Key Laboratory of Phytochemistry and Plant Resources in West China for measurements of the NMR, MS, IR, and UV spectral data.

## REFERENCES

1. T. G. Tutin, V. H. Heywood, N. A. Burges, D. H. Valentine, S. M. Walters, and D. A. Webb, *Flora Europaea*, **3**, Cambridge University Press, Cambridge, 1972, p. 122.
2. S. Mill, *Out of the Earth: the Essential Book of Herbal Medicine*, Viking Arkana, London, UK, 1991.
3. K. P. Odenthal, *Phytother. Res.*, **12**, S160 (1998).
4. E. Hoberg, B. Meier, and O. Sticher, *Planta Med.*, **66**, 352 (2000).
5. M. Ono, T. Yamasaki, T. Ikeda, M. Okawa, and J. Kinjo, *Chem. Pharm. Bull.*, **56**, 1621 (2008).
6. M. Ono, Y. Nagasawa, T. Ikeda, R. Tsuchihashi, M. Okawa, and J. Kinjo, *Chem. Pharm. Bull.*, **57**, 1132 (2009).
7. S. H. Li, H. J. Zhang, S. X. Qiu, X. M. Niu, B. D. Santarsiero, A. D. Mesecar, N. R. Farnsworth, and H. D. Sun, *Tetrahedron Lett.*, **43**, 5131 (2002).
8. E. Wollenweber and K. Mann, *Planta Med.*, **48**, 126 (1983).

9. C. Hirobe, Z. S. Qiao, K. Takeya, and H. Itokawa, *Phytochemistry*, **46**, 521 (1997).
10. C. Shao, J. Brent, W. Donna, N. Dejan, B. Richard, Z. Jim Wang, H. S. Fong, N. R. Farnsworth, and G. F. Pauli, *Fitoterapia*, **82**, 528 (2011).
11. K. Gorler, D. Ohlke, and H. Soicke, *Planta Med.*, **50**, 530 (1985).
12. B. Meier, D. Berger, E. Hoberg, O. Sticher, and W. Schaffner, *Phytomedicine*, **7**, 373 (2000).
13. P. G. Merz, C. Gorkow, A. Schrodter, S. Rietbrock, C. Sieder, D. Loew, J. S. Dericks-Tan, and H. D. Taubert, *Exp. Clin. Endocrinol. Diabetes*, **4**, 447 (1996).
14. Q. Gu, X. Zhang, Z. Jiang, J. Chen, and J. Zhou, *Zhongcaoyao*, **38**, 656 (2007).
15. H. Taguchi, *Chem. Pharm. Bull.*, **24**, 1668 (1976).
16. Y. S. Cheng and V. E. Rudloff, *Tetrahedron Lett.*, **14**, 1131 (1970).
17. M. Ono, Y. Ito, and T. Nohara, *Chem. Pharm. Bull.*, **49**, 1220 (2001).
18. K. Likhitwitayawuid, C. K. Angerhofer, G. A. Cordell, and J. M. Pezzuto, *J. Nat. Prod.*, **56**, 30 (1993).